共 177 条
[11]
Sandbach J(2014)Informed consent for pragmatic trials--the integrated consent model N Engl J Med 370 769-772
[12]
Hyman WJ(2014)Ethics and regulatory complexities for pragmatic clinical trials JAMA 311 2381-2382
[13]
Khandelwal P(2010)Management of febrile neutropenia: ESMO clinical practice guidelines Ann Oncol : official journal of the European Society for Medical Oncology 21 v252-v256
[14]
Negron AG(2009)Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735 J Clin Oncol 27 1177-1183
[15]
Richards DA(2011)Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group Eur J Cancer 47 215-220
[16]
Anthony SP(2011)Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres Curr Oncol 18 119-125
[17]
Mennel RG(2010)Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis Curr Oncol 17 2-3
[18]
Boehm KA(2009)High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide J Clin Oncol 27 e101-e102
[19]
Meyer WG(2014)Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis BMC Health Serv Res 14 189-e279
[20]
Asmar L(2016)Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE study Curr Oncol 23 e276-925